Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
Get Alerts ITCI Hot Sheet
Join SI Premium – FREE
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 2:30 pm PT.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular TherapiesIntra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.
Contact:
Intra-Cellular Therapies, Inc.Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations646-440-9333
Burns McClellan, Inc.Lisa Burns[email protected]212-213-0006
Source: Intra-Cellular Therapies Inc.
Source: Intra-Cellular Therapies Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
- OrthoSelect announces Partnership with Relu to provide automated CBCT integration for DIBS AI software
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sonder Holdings Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – SOND
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!